Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999199 | 0.87 | TMPRSS2 (0.33) | SLC16A3ASIC3 | |
| SCHEMBL21152853 | 0.85 | SLC16A3 (0.38) | SLC16A3AAK1FFAR1 | |
| SCHEMBL17469628 | 0.82 | ASIC3 (0.38) | SLC16A3AAK1FFAR1ASIC3 | |
| SCHEMBL17469730 | 0.81 | TMPRSS2 (0.48) | SLC16A3MEN1MAPTKMT2AASIC3 | |
| SCHEMBL18999200 | 0.74 | ASIC3 (0.38) | SLC16A3KLK1KLK5ASIC3 | |
| SCHEMBL17469632 | 0.73 | SLC16A3 (0.40) | SLC16A3MEN1MAPTKMT2ATSHR | |
| SCHEMBL21152726 | 0.73 | ASIC3 (0.39) | SLC16A3MRGPRX1ASIC3 | |
| SCHEMBL17469669 | 0.72 | TMPRSS2 (0.52) | SLC16A3MEN1MAPTKMT2AASIC3 | |
| SCHEMBL17469627 | 0.70 | CHRM2 (0.34) | SLC16A3 | |
| SCHEMBL17469629 | 0.68 | SLC16A3 (0.43) | SLC16A3MEN1MAPTKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
| WO-2016014674-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | SLC16A3 4161/4885AAK1 4258/4885KLK1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.